Biosimilars

The pan-Canadian Pharmaceutical Alliance (pCPA) Office released the monthly statistics for pCPA negotiations up to and including December 31, 2016.   To summarize, there were a total of 7 products with status changes: Three products added to the active list for a total of 43 active negotiations: Botox (multiple indications), Imbruvica (chronic lymphocytic leukemia/small lymphocytic leukemia), Rituxan SC. Two products concluded negotiations with an agreement: Grastofil, Metadol-D. Two products that…